<DOC>
	<DOCNO>NCT00809016</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure , PET scan , may determine extent cancer help doctor plan radiation therapy . Radiation therapy use high-energy x-ray kill tumor cell . Giving radiation therapy use 3-dimensional image tumor help focus thin beam radiation directly tumor , give radiation therapy high dos shorter period time , may kill tumor cell few side effect . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : This clinical trial study PET scan see well work patient head neck cancer undergo 3-dimensional conformal radiation therapy intensity-modulated radiation therapy .</brief_summary>
	<brief_title>PET Scans Patients With Head And Neck Cancer Who Are Undergoing 3-Dimensional Conformal Radiation Therapy And Intensity-Modulated Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess value pre-treatment PET determine target volume patient head neck cancer undergo three-dimensional conformational radiotherapy intensity-modulated radiotherapy . Secondary - To evaluate variation weekly fludeoxyglucose F 18 PET image first 5 week treatment . - To determine relationship change tumor metabolism radiotherapy control tumor 3 month 1 year post-treatment . OUTLINE : This multicenter study . Patients undergo fludeoxyglucose F18 PET ( FDG-PET ) addition conventional imaging baseline . Patients undergo standard three-dimensional conformational radiotherapy intensity-modulated radiation therapy 5 day week 5 week . Some patient also undergo weekly FDG-PET treatment .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm head neck cancer No nasopharyngeal paranasal sinus cancer Locally advance disease ( T3 T4 ) Not complete remission Planning undergo curative radiotherapy ( minimum dose 66 Gy ) , without standard treatment ( i.e. , platinumbased chemotherapy biological therapy/rituximab ) Measurable tumor accord RECIST criterion PATIENT CHARACTERISTICS : WHO performance status 02 Not pregnant nursing Able lie still 1 hour No history progressive neoplastic disease No known hypersensitivity fludeoxyglucose F18 excipients No severe uncontrolled systemic disease , include follow : Kidney disease Liver disease Cardiac disease Unstable uncompensated respiration Uncontrolled diabetes ( i.e. , glucose â‰¥ 1.5 g/L ) No geographical , social , psychological condition make followup impossible PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior surgery No concurrent experimental agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III basal cell carcinoma lip</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland acinic cell tumor</keyword>
	<keyword>salivary gland adenocarcinoma</keyword>
	<keyword>salivary gland adenoid cystic carcinoma</keyword>
	<keyword>salivary gland anaplastic carcinoma</keyword>
	<keyword>salivary gland malignant mixed cell type tumor</keyword>
	<keyword>salivary gland poorly differentiate carcinoma</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
</DOC>